GT Biopharma (GTBP) Other Non Operating Income (2010 - 2025)
GT Biopharma (GTBP) posted quarterly Other Non Operating Income of -$998000.0 for Q3 2025, down 739.74% quarter-over-quarter from $156000.0 in Q2 2025.
GT Biopharma (GTBP) Other Non Operating Income (2010 - 2025) Analysis & Trends
GT Biopharma (GTBP) has reported Other Non Operating Income for 14 consecutive years, with -$998000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non Operating Income changed N/A year-over-year to -$998000.0; the TTM figure through Dec 2025 stood at $156000.0 (changed N/A YoY), while the FY2025 annual figure was $156000.0, changed N/A from the prior year.
- Other Non Operating Income fell to -$998000.0 in Q3 2025 per GTBP's latest filing, from $156000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $998000.0 in Q1 2025 and bottomed at -$998000.0 in Q3 2025.
- Historically, Other Non Operating Income has averaged $37294.1 across 5 years, with a median of $27000.0 in 2024.
- On a YoY basis, Other Non Operating Income climbed as much as 6562.5% in 2023 and fell as far as 339.17% in 2023.
- GT Biopharma's Other Non Operating Income stood at $168000.0 in 2021, then plunged by 171.43% to -$120000.0 in 2022, then tumbled by 339.17% to -$527000.0 in 2023, then surged by 94.88% to -$27000.0 in 2024, then sank by 3596.3% to -$998000.0 in 2025.
- Business Quant data shows GTBP's Other Non Operating Income at -$998000.0 in Q3 2025, $156000.0 in Q2 2025, and $998000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -998,000.00 |
| Jun 30, 2025 | 156,000.00 |
| Mar 31, 2025 | 998,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | -527,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Jun 30, 2023 | 14,000.00 |
| Mar 31, 2023 | 533,000.00 |
| Dec 31, 2022 | -120,000.00 |
| Sep 30, 2022 | 107,000.00 |
| Jun 30, 2022 | 36,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 168,000.00 |
| Sep 30, 2021 | 502,000.00 |
| Jun 30, 2021 | -480,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | -931,000.00 |
| Sep 30, 2020 | 931,000.00 |
| Sep 30, 2017 | -1.45 Mn |